BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tayel A, Abd El Galil KH, Ebrahim MA, Ibrahim AS, El-Gayar AM, Al-Gayyar MM. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme. Eur J Pharmacol 2014;728:151-60. [PMID: 24530413 DOI: 10.1016/j.ejphar.2014.02.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Elewa MA, Al-Gayyar MM, Schaalan MF, Abd El Galil KH, Ebrahim MA, El-Shishtawy MM. Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clin Exp Metastasis 2015;32:479-93. [PMID: 25999065 DOI: 10.1007/s10585-015-9721-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
2 El-Far YM, Khodir AE, Noor AO, Almasri DM, Bagalagel AA, Diri RM, Kutbi HI, Al-Gayyar MMH. Selective cytotoxic activity and protective effects of sodium ascorbate against hepatocellular carcinoma through its effect on oxidative stress and apoptosis in vivo and in vitro. Redox Rep 2020;25:17-25. [PMID: 32172678 DOI: 10.1080/13510002.2020.1739870] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N. Heparanase: From basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat. 2016;29:54-75. [PMID: 27912844 DOI: 10.1016/j.drup.2016.10.001] [Cited by in Crossref: 113] [Cited by in F6Publishing: 111] [Article Influence: 18.8] [Reference Citation Analysis]
4 Heyman B, Yang Y. Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol 2016;44:1002-12. [PMID: 27576132 DOI: 10.1016/j.exphem.2016.08.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
5 Chioni AM, Grose RP. Biological Significance and Targeting of the FGFR Axis in Cancer. Cancers (Basel) 2021;13:5681. [PMID: 34830836 DOI: 10.3390/cancers13225681] [Reference Citation Analysis]
6 Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409-425. [PMID: 26105538 DOI: 10.1038/nrc3958] [Cited by in Crossref: 783] [Cited by in F6Publishing: 769] [Article Influence: 111.9] [Reference Citation Analysis]
7 Supramaniam A, Liu X, Ferro V, Herrero LJ. Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice. Antimicrob Agents Chemother 2018;62:e01959-17. [PMID: 29437628 DOI: 10.1128/AAC.01959-17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
8 Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, Gliksman M, Goy A, Suh KS. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget 2016;7:44735-62. [PMID: 27007053 DOI: 10.18632/oncotarget.8203] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 18.5] [Reference Citation Analysis]
9 Gerlza T, Trojacher C, Kitic N, Adage T, Kungl AJ. Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Semin Thromb Hemost 2021;47:316-32. [PMID: 33794555 DOI: 10.1055/s-0041-1725067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gaskin SM, Soares Da Costa TP, Hulett MD. Heparanase: Cloning, Function and Regulation. Adv Exp Med Biol 2020;1221:189-229. [PMID: 32274711 DOI: 10.1007/978-3-030-34521-1_7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Al-Gayyar MMH, Bagalagel A, Noor AO, Almasri DM, Diri R. The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB. Biomed Pharmacother 2019;112:108653. [PMID: 30784932 DOI: 10.1016/j.biopha.2019.108653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
12 Muhammad RS, Abu-Saleh N, Kinaneh S, Agbaria M, Sabo E, Grajeda-Iglesias C, Volkova N, Hamoud S. Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E0 mice. Atherosclerosis 2018;276:155-62. [PMID: 30075439 DOI: 10.1016/j.atherosclerosis.2018.07.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
13 Alyoussef A, Taha M. Antitumor activity of sulforaphane in mice model of skin cancer via blocking sulfatase-2. Exp Dermatol 2019;28:28-34. [PMID: 30315662 DOI: 10.1111/exd.13802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sherif IO, Al-Mutabagani LA, Sabry D, Elsherbiny NM. Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression. Int J Mol Sci 2020;21:E7642. [PMID: 33076548 DOI: 10.3390/ijms21207642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Metwaly HA, El-Gayar AM, El-Shishtawy MM. Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats. Arch Biochem Biophys 2018;652:50-8. [PMID: 29928859 DOI: 10.1016/j.abb.2018.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Alshehri MA, Alshehri MM, Albalawi NN, Al-Ghamdi MA, Al-Gayyar MMH. Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma. Oncol Lett 2021;21:173. [PMID: 33552290 DOI: 10.3892/ol.2021.12434] [Reference Citation Analysis]
17 Hassan HFH, Mansour AM, Abo-youssef AMH, Elsadek BEM, Messiha BAS. Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence. Clin Exp Pharmacol Physiol 2017;44:235-43. [DOI: 10.1111/1440-1681.12681] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
18 Giannini G, Battistuzzi G, Rivara S. The Control of Heparanase Through the Use of Small Molecules. Adv Exp Med Biol 2020;1221:567-603. [PMID: 32274727 DOI: 10.1007/978-3-030-34521-1_23] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Hassoun SM, Abdel-rahman N, Eladl EI, El-shishtawy MM. Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway. Tumour Biol 2017;39:101042831770737. [DOI: 10.1177/1010428317707376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
20 Guo S, Wu X, Lei T, Zhong R, Wang Y, Zhang L, Zhao Q, Huang Y, Shi Y, Wu L. The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance. Front Cell Dev Biol 2022;9:784983. [DOI: 10.3389/fcell.2021.784983] [Reference Citation Analysis]
21 Wang P, Koyama Y, Liu X, Xu J, Ma HY, Liang S, Kim IH, Brenner DA, Kisseleva T. Promising Therapy Candidates for Liver Fibrosis. Front Physiol. 2016;7:47. [PMID: 26909046 DOI: 10.3389/fphys.2016.00047] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 6.5] [Reference Citation Analysis]
22 Mohan CD, Hari S, Preetham HD, Rangappa S, Barash U, Ilan N, Nayak SC, Gupta VK, Basappa, Vlodavsky I, Rangappa KS. Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds. iScience 2019;15:360-90. [PMID: 31103854 DOI: 10.1016/j.isci.2019.04.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]